Hydrophilic Asn-Asn-Linker Adcs for Potent and Stable Targeted Immunotherapy
This invention introduces hydrophilic TLR7 agonist antibody drug conjugates using a short Asn Asn linker that improves solubility, stability, and pharmacokinetics. By enabling precise site specific conjugation with reduced aggregation and strong innate immune activation, the platform delivers potent antitumor responses across multiple solid tumor indications.
Background:...
Published: 11/14/2025
|
Inventor(s): Lawrence Tumey, Mohan Mullapudi
Keywords(s): Technologies
Category(s): Campus > Binghamton University
|